Blue Fin Capital Inc. cut its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 0.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,288 shares of the company’s stock after selling 167 shares during the period. Merck & Co., Inc. makes up approximately 0.9% of Blue Fin Capital Inc.’s investment portfolio, making the stock its 24th biggest position. Blue Fin Capital Inc.’s holdings in Merck & Co., Inc. were worth $3,411,000 at the end of the most recent reporting period.
A number of other hedge funds have also made changes to their positions in MRK. Bare Financial Services Inc bought a new position in Merck & Co., Inc. during the fourth quarter valued at about $28,000. Rakuten Securities Inc. bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at about $30,000. RIA Advisory Group LLC acquired a new position in shares of Merck & Co., Inc. in the 4th quarter worth approximately $30,000. Ruedi Wealth Management Inc. raised its holdings in shares of Merck & Co., Inc. by 180.2% in the 3rd quarter. Ruedi Wealth Management Inc. now owns 311 shares of the company’s stock worth $32,000 after purchasing an additional 200 shares in the last quarter. Finally, AlphaMark Advisors LLC acquired a new stake in Merck & Co., Inc. during the fourth quarter valued at approximately $34,000. Institutional investors and hedge funds own 76.07% of the company’s stock.
Insider Activity at Merck & Co., Inc.
In related news, insider Joseph Romanelli sold 1,000 shares of the stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total value of $124,890.00. Following the transaction, the insider now owns 19,569 shares in the company, valued at $2,443,972.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.09% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
View Our Latest Stock Report on MRK
Merck & Co., Inc. Stock Down 0.6 %
Shares of NYSE:MRK traded down $0.75 during trading on Friday, reaching $127.51. 6,221,928 shares of the company traded hands, compared to its average volume of 6,932,243. The firm has a fifty day simple moving average of $126.45 and a 200 day simple moving average of $116.75. The company has a quick ratio of 1.00, a current ratio of 1.25 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a 1-year low of $99.14 and a 1-year high of $133.10. The firm has a market cap of $322.99 billion, a P/E ratio of 141.68, a price-to-earnings-growth ratio of 1.63 and a beta of 0.39.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its quarterly earnings data on Thursday, April 25th. The company reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.94 by $0.13. Merck & Co., Inc. had a return on equity of 14.15% and a net margin of 3.76%. The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.21 billion. During the same quarter last year, the firm earned $1.40 earnings per share. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. Analysts anticipate that Merck & Co., Inc. will post 8.69 earnings per share for the current fiscal year.
Merck & Co., Inc. Company Profile
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
See Also
- Five stocks we like better than Merck & Co., Inc.
- What is the Hang Seng index?
- MarketBeat Week in Review – 4/29 – 5/3
- Golden Cross Stocks: Pattern, Examples and Charts
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- The How And Why of Investing in Oil Stocks
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.